EDGAR·FLOW

PTC THERAPEUTICS, INC. — Form 8-K

Filed September 21, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
PTC Therapeutics completed acquisition of ST-920 (isaralgagene civaparvovec), a one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics. Rolling BLA submission to FDA expected Q4 2026. ST-920 has Orphan Drug, Fast Track, and RMAT designations from FDA. Specific acquisition price not disclosed in filing.
Why this rating

Major pipeline addition for $3.4B company; BLA-stage asset with regulatory designations reduces development risk; gene therapy addresses large unmet need in rare disease. Timing and valuation undisclosed limits certainty.

Tradability signal
NO TRADE

No trade: positive news with only +0.2% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.54% over 4 hrs, n=45). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$65.26 ▲ 0.00%
at our read · unknown
$65.26
+10 min · unknown
$65.89 ▲ 0.97%
+30 min · unknown
$66.03 ▲ 1.19%
+1 hr · unknown
$65.96 ▲ 1.07%
+4 hrs · unknown
$65.72 ▲ 0.70%

The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ PTCT · stock on Yahoo Finance ↗

See more from September 21, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.